Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 13Other hematologic neoplasm 12Dermatologic 6Other solid neoplasm 5Genitourinary 4Sarcoma 2Myeloid 2Plasma cell 1Other neoplasm 1Head & Neck 1Gynecologic 1Gastrointestinal 1Endocrine 1CNS 1Breast 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Carcinoma, Medullary 1Adenocarcinoma, Follicular 1

Interventions

Magnetic Resonance Spectroscopy 17Specimen Handling 13lutetium Lu 177 dotatate 7gallium Ga 68 dotatate 7Cisplatin 7cabozantinib 6pazopanib 5Sorafenib 5Fluorodeoxyglucose F18 5Everolimus 5Etoposide 4romidepsin 3olaparib 3fluorodopa F 18 3cixutumumab 3X-Rays 3Temozolomide 3Sunitinib 3Radiotherapy 3Nivolumab 3Ipilimumab 3Iodine-131 3CTLA-4 Antigen 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3tipifarnib 2belinostat 2aldesleukin 2aflibercept 2Vorinostat 2Trastuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × tanespimycin × Endocrine × Clear all
NCT00118248 2017-02-15

Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Completed
41 enrolled 10 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡